Plaque Psoriasis

Dr Linda Stein Gold shares a clinical pearl on taking care of patents with plaque psoriasis from her practice.

Expert dermatologist shares recent data on systemic therapy for patients with moderate psoriasis.

These new findings show promise for patient-reported outcomes, though additional research may be warranted to assess other measurement properties of the DermSat-7.

During this interview segment, Dr. Deodhar described his presentation at the ACR 2023 convergence on longitudinal data regarding bimekizumab for patients with this condition.

Expert dermatologists discuss the paradigm shift occurring in the management of plaque psoriasis as a result of the expanded array of treatment options.

Expert dermatologists highlight the benefits of head-to-head trials for various agents for the management of plaque psoriasis and review the top-line results of a study comparing risankizumab and apremilast.

During this interview segment, Dr. Chovatiya further analyzed the updated National Psoriasis Foundation consensus statements for GPP and the future of treatment research.

The PEAUrigami art exhibit was designed to educate participants to better understand the pathophysiology of skin using origami artwork with skin pattern-printed papers.

Dr Linda Stein Gold discusses the shift in the treatment paradigm in plaque psoriasis.

Dr Linda Stein Gold summarizes results from head-to-head trials in plaque psoriasis.

In this interview, Dr. Chovatiya summarized and discussed the updated National Psoriasis Foundation consensus statements for GPP.

sLOX-1 was positively associated with high-risk coronary plaque features in patients with psoriasis and increased inflammation.

This research provides an early analysis of plaque psoriasis patients within routine clinical practice settings and outside of a clinical trial setting.

Individuals with intermediate polysocial risk scores had a 1.2 times higher risk of developing psoriasis, while those with high polysocial risk scores had a 1.5 times higher risk.

A randomized trial examining acupuncture in people with CSU suggests use of acupuncture could improve UAS7 scores in these patients, but investigators noted this failed to reach the threshold for significance.

Results showed significant improvements in serum HDL, CRP, and ESR after treatment with biologic therapies

Expert dermatologists review the efficacy of IL-23 inhibitors for plaque psoriasis in the real world, highlighting the opportunity to individualize treatment.

Expert dermatologist Dr Linda Stein Gold discusses the pathophysiology of psoriasis as target for treatment.

Dr Linda Stein Gold discusses the effect that plaque psoriasis in special areas can have on the quality of life of a patient.

Expert dermatologists share how the understanding of the pathophysiology of plaque psoriasis guides approaches to therapy.

Drs Bruce Strober, Benjamin Lockshin, and Jennifer Soung discuss how plaque psoriasis impacts a patient’s quality of life, focusing on patient-reported outcome measurements as well as special areas affected by plaque psoriasis.

Secukinumab (Cosentyx) becomes the first IL-17A inhibitor, as well as the first drug since 2015, approved to treat adults with moderate to severe HS.

Guselkumab effectively cleared the skin of patients with moderate-to-severe plaque psoriasis across all skin tones, with significant improvements observed within the first 16 weeks of treatment.

Experts share practice pearls for managing patients with plaque psoriasis, highlighting the need to educate health care providers about any dermatologic therapy before they commit to treating a patient.

Experts discuss access to treatment as one of the biggest barriers in plaque psoriasis and highlight the importance of individualizing therapy for each patient.

Patients with moderate to severe scalp psoriasis treated with tildrakizumab exhibited sustained efficacy through week 52, demonstrating the long-term effectiveness and safety profile of this treatment.

Patients in the deucravacitinib group had higher response rates compared with placebo at week 16, regardless of the extent of baseline PASI score or BSA involvement.

Patients with scalp and body psoriasis who used nonsteroidal roflumilast foam .3% once daily experienced significant symptom improvement as early as 2 weeks.

Dr. Song spoke in this segment of his interview on several more insightful elements from his presentation titled ‘Early Dermatology Practice Pearls.’

Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.